To compound the idea of YAP/TAZ acting as tumour suppressors or oncogenes in this binary fashion, a recent study leveraged mice models of cholangiocarcinoma and hepatocellular carcinoma to study the impact of YAP/TAZ dysregulation in peritumoral immune cells. Here, YAP1 is linked to hepatocellular carcinoma.